85 related articles for article (PubMed ID: 25202110)
1. Optimal treatment change criteria for advanced gastric cancer with non-measurable peritoneal metastasis: symptom/tumor marker-based versus CT-based.
Hasegawa H; Fujitani K; Nakazuru S; Hirao M; Yamamoto K; Mita E; Tsujinaka T
Anticancer Res; 2014 Sep; 34(9):5169-74. PubMed ID: 25202110
[TBL] [Abstract][Full Text] [Related]
2. Neoadjuvant intraperitoneal and systemic chemotherapy for gastric cancer patients with peritoneal dissemination.
Fujiwara Y; Takiguchi S; Nakajima K; Miyata H; Yamasaki M; Kurokawa Y; Okada K; Mori M; Doki Y
Ann Surg Oncol; 2011 Dec; 18(13):3726-31. PubMed ID: 21584835
[TBL] [Abstract][Full Text] [Related]
3. Neoadjuvant docetaxel, capecitabine and cisplatin (DXP) in patients with unresectable locally advanced or metastatic gastric cancer.
Sym SJ; Chang HM; Ryu MH; Lee JL; Kim TW; Yook JH; Oh ST; Kim BS; Kang YK
Ann Surg Oncol; 2010 Apr; 17(4):1024-32. PubMed ID: 19941081
[TBL] [Abstract][Full Text] [Related]
4. Weekly paclitaxel as second-line chemotherapy in Japanese patients with advanced gastric cancer.
Kadokura M; Iwasa S; Honma Y; Kato K; Hamaguchi T; Yamada Y; Enomoto N; Shimada Y
Anticancer Res; 2013 Oct; 33(10):4547-52. PubMed ID: 24123029
[TBL] [Abstract][Full Text] [Related]
5. A phase 2 trial of intravenous and intraperitoneal paclitaxel combined with S-1 for treatment of gastric cancer with macroscopic peritoneal metastasis.
Yamaguchi H; Kitayama J; Ishigami H; Emoto S; Yamashita H; Watanabe T
Cancer; 2013 Sep; 119(18):3354-8. PubMed ID: 23798046
[TBL] [Abstract][Full Text] [Related]
6. Docetaxel monotherapy as a second-line treatment after failure of fluoropyrimidine and platinum in advanced gastric cancer: experience of 154 patients with prognostic factor analysis.
Jo JC; Lee JL; Ryu MH; Sym SJ; Lee SS; Chang HM; Kim TW; Lee JS; Kang YK
Jpn J Clin Oncol; 2007 Dec; 37(12):936-41. PubMed ID: 18211985
[TBL] [Abstract][Full Text] [Related]
7. Induction chemotherapy with S-1 plus cisplatin followed by surgery for treatment of gastric cancer with peritoneal dissemination.
Okabe H; Ueda S; Obama K; Hosogi H; Sakai Y
Ann Surg Oncol; 2009 Dec; 16(12):3227-36. PubMed ID: 19777180
[TBL] [Abstract][Full Text] [Related]
8. Combination of low-dose docetaxel and standard-dose S-1 for the treatment of advanced gastric cancer: efficacy, toxicity, and potential predictive factor.
Cui Y; Li Q; Yu Y; Chen Y; Feng Y; Wang Y; Liu T
Cancer Chemother Pharmacol; 2013 Jan; 71(1):145-52. PubMed ID: 23064955
[TBL] [Abstract][Full Text] [Related]
9. Combination chemotherapy with capecitabine (X) and Cisplatin (P) as first line treatment in advanced gastric cancer: experience of 223 patients with prognostic factor analysis.
Lee SS; Lee JL; Ryu MH; Chang HM; Kim TW; Kang HJ; Kim WK; Lee JS; Kang YK
Jpn J Clin Oncol; 2007 Jan; 37(1):30-7. PubMed ID: 17272321
[TBL] [Abstract][Full Text] [Related]
10. Diagnostic laparoscopy, serum CA125, and peritoneal metastasis in gastric cancer.
Fujimura T; Kinami S; Ninomiya I; Kitagawa H; Fushida S; Nishimura G; Kayahara M; Shimizu K; Ohta T; Miwa K
Endoscopy; 2002 Jul; 34(7):569-74. PubMed ID: 12170412
[TBL] [Abstract][Full Text] [Related]
11. [Clinical effect of intraoperative peritoneal hyperthermic chemotherapy for advanced gastric cancer].
Zhu ZG; Tang R; Yan M; Chen J; Yang QM; Li S; Yao XX; Zhang J; Yin HR; Lin YZ
Zhonghua Wei Chang Wai Ke Za Zhi; 2006 Jan; 9(1):26-30. PubMed ID: 16437366
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of S-1 for patients with peritoneal metastasis of gastric cancer.
Ishizone S; Maruta F; Saito H; Koide N; Sugiyama A; Nakayama J; Miyagawa S
Chemotherapy; 2006; 52(6):301-7. PubMed ID: 17008790
[TBL] [Abstract][Full Text] [Related]
13. Intraperitoneal docetaxel combined with S-1 for advanced gastric cancer with peritoneal dissemination.
Fujiwara Y; Takiguchi S; Nakajima K; Miyata H; Yamasaki M; Kurokawa Y; Mori M; Doki Y
J Surg Oncol; 2012 Jan; 105(1):38-42. PubMed ID: 21882194
[TBL] [Abstract][Full Text] [Related]
14. Prognostic factors in patients with advanced gastric cancer treated by noncurative resection: a multivariate analysis.
Tsujitani S; Oka S; Suzuki K; Saito H; Kondo A; Ikeguchi M; Maeta M; Kaibara N
Hepatogastroenterology; 2001; 48(41):1504-8. PubMed ID: 11677996
[TBL] [Abstract][Full Text] [Related]
15. Diffuse type advanced gastric cancer showing dismal prognosis is characterized by deeper invasion and emerging peritoneal cancer cell: the latest comparative study to intestinal advanced gastric cancer.
Yamashita K; Sakuramoto S; Katada N; Futawatari N; Moriya H; Hirai K; Kikuchi S; Watanabe M
Hepatogastroenterology; 2009; 56(89):276-81. PubMed ID: 19453074
[TBL] [Abstract][Full Text] [Related]
16. Therapeutic outcomes of continuous hyperthermic peritoneal perfusion against advanced gastric cancer with peritoneal carcinomatosis.
Kunisaki C; Shimada H; Akiyama H; Nomura M; Matsuda G; Otsuka Y; Ono H; Takahashi M
Hepatogastroenterology; 2006; 53(69):473-8. PubMed ID: 16795995
[TBL] [Abstract][Full Text] [Related]
17. Posttherapy nodal status, not graded histologic response, predicts survival after neoadjuvant chemotherapy for advanced gastric cancer.
Fujitani K; Mano M; Hirao M; Kodama Y; Tsujinaka T
Ann Surg Oncol; 2012 Jun; 19(6):1936-43. PubMed ID: 22187120
[TBL] [Abstract][Full Text] [Related]
18. [Strategy of treatment for gastric cancer with peritoneal metastasis].
Tanemura H; Oshita H; Yamada M; Hatoh T; Adachi T; Matsui K
Gan To Kagaku Ryoho; 2010 Mar; 37(3):443-6. PubMed ID: 20332680
[TBL] [Abstract][Full Text] [Related]
19. [Therapeutic efficacy of intra-peritoneal infusion of cisplatin and continuous intravenous infusion of 5-fluorouracil in gastric cancer patients with peritoneal metastasis].
Terashima M; Takagane A; Oyama K; Abe K; Araya M; Yonezawa H; Irinoda T; Nakaya T; Shimooki O; Inaba T; Fujiwara H; Saito K
Gan To Kagaku Ryoho; 1999 Oct; 26(12):1806-8. PubMed ID: 10560399
[TBL] [Abstract][Full Text] [Related]
20. Salvage gastrectomy after intravenous and intraperitoneal paclitaxel (PTX) administration with oral S-1 for peritoneal dissemination of advanced gastric cancer with malignant ascites.
Kitayama J; Ishigami H; Yamaguchi H; Yamashita H; Emoto S; Kaisaki S; Watanabe T
Ann Surg Oncol; 2014 Feb; 21(2):539-46. PubMed ID: 23975319
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
